Skip to main content
. Author manuscript; available in PMC: 2022 Jul 25.
Published in final edited form as: J Natl Compr Canc Netw. 2019 Jul 1;17(7):813–820. doi: 10.6004/jnccn.2018.7281

Table 4:

Association Between Clinical Characteristics and Surveillance Advanced Imaging Use

Variable Odds Ratio (95% Confidence Interval) P-Value
Age 0.41
 < 45 1.18 (0.84, 1.67)
 45–54 1.27 (0.96, 1.67) --
 55–64 (Reference) -- -- --
 65–74 1.18 (0.85, 1.63) --
 75+ 1.43 (0.97, 2.11) --
Race 0.93
 White (Reference) -- --
 Non-White 1.02 (0.71, 1.46) --
Diagnosis Year <0.01
 2007–2012 (Reference) -- --
 2013–2014 0.68 (0.52, 0.89) --
Stage <0.01
 Stage 0 0.55 (0.38, 0.80) --
 Stage I (Reference) -- --
 Stage II 1.85 (1.45, 2.37) --
 Stage III 3.65 (2.48, 5.38) --
ER 0.33
 Positive 0.82 (0.54, 1.23) --
 Negative (Reference) -- --
PR 0.36
 Positive 0.85 (0.60, 1.20) --
 Negative (Reference) -- --
HER2 0.96
 Positive 0.99 (0.64, 1.52) --
 Negative (Reference) -- --
Curative Therapy 0.86
 Mastectomy (Reference) -- --
 Lumpectomy + Radiation 0.98 (0.78, 1.23) --
Family History 0.63
 Yes 1.07 (0.82, 1.38) --
 No (Reference) -- --
Genetic Mutation 0.46
 Yes 1.30 (0.65, 2.60) --
 No (Reference) -- --
Tumor Marker Use (Peri-diagnostic) 0.04
 Yes 1.35 (1.01, 1.80) --
 No (Reference) -- --
Tumor Marker Use (Surveillance) 0.19
 Yes 0.86 (0.68, 1.08) --
 No (Reference) -- --
Advanced Imaging Use (Peri-diagnostic) <0.01
 Yes 1.76 (1.33, 2.31) --
 No (Reference) -- --